Optimizing regulatory T cells for therapeutic application in human organ transplantation. Issue 5 (October 2018)

• Record Type: Journal Article
• Authors: Vaikunthanathan, Trishan; Safinia, Niloufar; Lombardi, Giovanna
• Is Part Of: Current opinion in organ transplantation. Volume 23:Issue 5(2018:Oct.)
• Publication Date: 2018-10
• Subjects: cell therapy -- immunotherapy -- regulatory T cells -- tolerance -- transplantation; Transplantation of organs, tissues, etc -- Periodicals; Immunosuppression -- Periodicals; Transplantation immunology -- Periodicals; 617.954
• DOI: 10.1097/MOT.0000000000000561
• Languages: English
• ISSNs: 1087-2418

Abstract

Abstract : Purpose of review: Initial clinical trials of adoptive regulatory T-cell (Treg) therapy in solid organ transplantation have proven to be both feasible and well tolerated. With Phase 2 trials underway, efforts have been focused on the optimization of the Treg product. Recent findings: With science and our knowledge on the biology of these cells constantly advancing, we have been able to refine our search for a Treg population that would be ideally suited for therapeutic application. This idealized population must be readily isolated, allow for in-vitro expansion, demonstrate potent and specific suppressor function, maintain lineage stability and demonstrate a relevant homing profile. With the advent of innovative cell analysis/isolation techniques and genetic modifications, we are able to choose and design Tregs to fulfil these criteria. Summary: By utilizing advances in science and technology, we can optimize Treg therapy in human organ transplantation maximizing their prospects in the arena of transplantation tolerance.